Cisplatin-induced gastric paresis

Cohen, Steven C.; Mollman, Joan E.

doi:10.1007/bf00151227

Cited by 13 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Other signs include gait disturbances due to defective proprioception, depressed tendon reflexes, decrease of vibratory, touch, and pain sensitivity, 39,40,45 and autonomic dysfunction. 4,9,40 Electrophysiological evaluations show slowing of sensory nerve conduction and reduction of the amplitude of the nerve action potentials, with minimal or absent motor involvement. 5,10,38,39 Slowing of central conduction velocity, measured by somatosensory evoked potentials, has been reported after cumulative doses of 200-400 mg/m 2 .…”

mentioning

confidence: 99%

Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice

et al. 1999

View full text Add to dashboard Cite

mentioning

confidence: 99%

Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice

et al. 1999

View full text Add to dashboard Cite

“…Chemotherapy-induced gastroparesis has been well recognized as a rare but careful complication with high-dose chemotherapy such as myeloablative regimens prior to bone marrow transplantation in blood cancers by several case reports ( 6 , 7 ). However, there is an only one case report of this disease in chemotherapy for solid cancer, which was published in 1980s ( 8 ). This report also suggested that gastroparesis might be an adverse event as a cumulative toxicity of platinum-based chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid caner: a case report

Nakayama¹,

Haratani²,

Kurosaki³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background Proper management of chemotherapy-related gastrointestinal toxicities is essential to maximize therapeutic outcome for malignancies. Gastroparesis is an onerous syndrome characterized by delayed gastric emptying without gastrointestinal obstruction, but this has not been recognized as chemotherapy-related complication in solid malignancies. Here, we describe a case of gastroparesis possibly caused by neurotoxicity of taxane and platinum-based high-intensity chemotherapy against solid cancer. Case Description A 73-year-old male was diagnosed with stage IVA oropharyngeal cancer (cT4N2bM0) as a cause of swallowing difficulty. As a curative treatment of the oropharyngeal cancer, induction chemotherapy with the regimen of docetaxel, cisplatin and fluorouracil (TPF) was initiated with nutritional support by nasogastric tube feeding. Then, this case was complicated with late-onset gastric dysmotility as evidenced by abnormally dilated stomach even after cessation of feeding for more than a few days. After a careful exclusion of other diseases that could cause gastric dysmotility, we eventually diagnosed chemotherapy-induced gastroparesis as a cause of his symptom. Notably, this refractory gastroparesis was successfully controlled with 5-HT4 agonist, mosapride, resulting in recovery of gastric motility and safe completion of the subsequent curative treatment. Conclusions Despite its rarity in patients with solid cancers, it is important to note chemotherapy-induced gastroparesis because delay in its management can be detrimental to their survival outcome. Thus, oncologists should consider gastroparesis in evaluating persistent upper abdominal symptoms after neurotoxic chemotherapies for solid cancer.

show abstract

“…Chemotherapy-induced gastroparesis has been recognized as a rare complication of high-dose chemotherapy such as myeloablative regimens prior to bone marrow transplantation in patients with blood cancers [5,6]. However, as far as we are aware, there is only one case report of this condition associated with chemotherapy for solid tumors [7]. This report from 1987 also suggested that gastroparesis might result from cumulative toxicity of platinum-based chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid cancer

Nakayama

Haratani

Kurosaki

et al. 2021

Preprint

View full text Add to dashboard Cite

Proper management of chemotherapy-related gastrointestinal toxicities is essential to maximize therapeutic outcome for malignancies. Gastroparesis is characterized by delayed gastric emptying without gastrointestinal obstruction. Although it has not been well recognized as a complication of chemotherapy for solid malignancies, we here report a case of gastroparesis apparently due to neurotoxicity of high-intensity taxane- and platinum-based chemotherapy for a solid tumor. The patient experienced late-onset gastric dysmotility as evidenced by an abnormally dilated stomach even after cessation of feeding for several days. The gastroparesis was successfully controlled with a 5-HT4 receptor agonist, resulting in recovery of gastric motility and allowing completion of curative anticancer treatment. Despite its rarity in patients with solid cancers, gastroparesis should be recognized as a potential cause of persistent upper abdominal symptoms during neurotoxic chemotherapy in such individuals, given that a delay in its management may be detrimental to survival outcome.

show abstract

Cisplatin-induced gastric paresis

Cited by 13 publications

References 18 publications

Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice

Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice

Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid caner: a case report

Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid cancer

Contact Info

Product

Resources

About